Panacea Biotec LimitedNSE: PANACEABIO

Unaudited Financial Results for quarter ended June 30, 2025

· Issued by Panacea Biotec Limited


August 14, 2025

The Manager, Listing Department

The National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051

NSE Symbol: PANACEABIO

BSE Limited

Corporate Relationship Department, Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai - 400 001 BSE Scrip Code: 531349

Sub: (1) Standalone and Consolidated Unaudited Financial Results (Provisional) along with Limited Review Report for the quarter ended 30.06.2025 (2) (i) Date, time and venue of 41stAGM - Tuesday, 30.09.2025 at 11:30 A.M.; and (ii) Dates of Book Closure - 26.09.2025 to 30.09.2025 Ref: Regulation 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

In continuation to our letter dated August 04, 2025, and pursuant to Regulations 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), we would like to inform you that:

  1. The Board of Directors has at its meeting held today, i.e. August 14, 2025, inter-alia, considered and approved the Standalone and Consolidated Unaudited Financial Results of the Company (which have been subjected to Limited Review by the Statutory Auditors) for the quarter ended June 30, 2025. The same was also reviewed by the Audit Committee in its meeting held on August 13, 2025. A copy of the said results along with the Limited Review Report is enclosed as Annexure - A.

    Pursuant to Regulation 46(2)(l) of the SEBI LODR Regulations, the aforesaid statements of financial results are being uploaded on the website of the Company i.e. https://www.panaceabiotec.com.

    Further, pursuant to Regulation 47(1)(b) of the SEBI LODR Regulations, the Quick Response Code and the details of the webpage where complete financial results of the Company for the quarter ended June 30, 2025, are accessible to the Investors, is being sent for publication in newspapers.

    Panacea Biotec Ltd (CIN: L33117PB1984PLC022350)

    Regd. Office : Ambala Chandigarh Highway, Lalru - 140501, Punjab

    Vinod Goel

    Digitally signed by Vinod Goel Date: 2025.08.14

    17:32:24 +05'30'

    Correspondence/Corporate office : B-1 Extn../G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India Ph.: 91-11-4167 9000, 4167 8000, Email: companysec@panaceabiotec.com



  2. The Board of Directors has also decided that:

    1. the 41stAnnual General Meeting of the Company will be held on Tuesday, September 30, 2025at 11:30 A.M. through Video Conferencing / Other Audio-Visual Means; and

    2. the Register of Members and Share Transfer Books will remain closed from Friday, September 26, 2025, to Tuesday, September 30, 2025(both days inclusive) for the purpose of Annual General Meeting.

The meeting of the Board of Directors commenced at 11:30 A.M. and concluded at 04:45 P.M. This is for your information and records please.

Thanking you Sincerely yours,

for Panacea Biotec Limited

Vinod Goel

Vinod Goel

Digitally signed by Vinod Goel Date: 2025.08.14

17:32:51 +05'30'

Group CFO and Head Legal & Company Secretary

Encls: As above

Panacea Biotec Ltd (CIN: L33117PB1984PLC022350)

Regd. Office : Ambala Chandigarh Highway, Lalru - 140501, Punjab Correspondence/Corporate office : B-1 Extn../G-3, Mohan Co-op. Indl. Estate, Mathura Road, New Delhi - 110 044, India

Ph.: 91-11-4167 9000, 4167 8000, Email: companysec@panaceabiotec.com

(� in Lakh except per share)

f'

I Panacea Biotec

lrnov,1tto" In ...uoport ot l1f("

Extract of Standalone and Consolidated Financial Results (Unaudited) for the Quarter Ended June 30, 2025

Particulars

Standalone

Consolidated

Quarter Ended

Year Ended

Quarter Ended

Year Ended

June 30,

2025

March 31,

2025

June 30,

2024

March 31,

2025

June 30,

2025

March 31,

2025

June 30,

2024

March 31,

2025

(Unaudited)

Audited (Refer note 3)

(Unaudited)

(Audited)

(Unaudited)

Audited (Refer note 3)

(Unaudited)

(Audited)

Total income from operations

11,225

6,790

5,688

30,985

16,670

13,253

11,572

55,909

Net Profit / (Loss) for the period/year (before tax, exceptional and/or extraordinary item)

(884)

(2,203)

(1,498)

(2,606)

(476)

(1,979)

(4,394)

Net Profit / (Loss) for the period/year before tax (after exceptional and/or extraordinary item)

(884)

(2,203)

(1,498)

(2,606)

656

(1,705)

(795)

Net Profit / (Loss) for the period/year after tax (after exceptional and/or extraordinary item)

(670)

(1,239)

(1,378)

(1,523)

396

(199)

(1,588)

(872)

Total comprehensive income/(loss) for the period/year (comprising of profit/(loss) for the period/year (after tax) and other comprehensive income (after tax))

(668)

(1,229)

613

(1,378)

613

(1,518)

613

613

(63)

613

(1,585)

613

(761)

Equity Share Capital (face value of�1 per share)

613

613

Eaming/(loss) per equity share, (annualised, except for quarters): Basic and Diluted

(1.09)

(2.02)

(2.25)

(2.49)

0.66

(0.31)

(2.59)

(2,775)

(1.37)

(4)

394

Notes:

I The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results is available on the Stock Exchanges websites, NSE- https://http://https://www.nseindia.com, BSE- https://http://https://www.bseindia.com and is also available on the Company's website, https://http://https://www.panaceabiotec.com.

  1. The said financial results for the Quarter Ended June 30, 2025 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meetings held on August 13, 2025 and August 14, 2025 respectively and have been approved by the statutory auditors ofthe Company.

  2. Amounts for the quarters ended March 3 J, 2025 represent the balancing amounts between the audited amounts for the full financial year and published year to date amounts upto the third quarter ofthe respective financial years, which had been subjected only to limited review.

  3. The financial results have been prepared in accordance with the recognition and measurement principles of applicable Indian Accounting Standard ("Ind-AS") notified under the Companies (Indian Accounting Standards) Rules, 2015 as specified in section 133 of the Companies Act, 2013.

  4. Previous period / year amounts have been regrouped/ reclassitied to make them comparable with those of current period/ year.

Place: New Delhi Date: August 14, 2025

I

Panacea Biotec Limited

Regd. Office : Ambala-Chandigarh Highway, Lalru- 140501, Punjab CIN: L33 l l 7PB I 984PLC022350 - Ph. No. 91-11-4 I 679000, Fax: 91-11-4 I 679070,

Website: https://www panacea-biotec.com, E-mail: Corporate@panaceabiotec.com

For and on behalf of the Board of Directors of Panacea Biotec Limited

Dr. Rajesh Jain Chairman & Managing Director

�-



�/ Panacea Biotec

lnnov.-.it1c,11 •n •,ur,pnrr nf lit<•

Statement ofStandalone andConsolidatedFinancial Results (Unaudited) for theQuarter EndedJuneJO, 2025

(fin Lakh except per share)

S.No Particulars

Standalone

Quarter Ended

495

745

YearEnded

Consolidated Quarter Ended

Year Ended

5,937

(795)

477

76

839

JuneJO, 2025

MarchJI, 2025

JuneJO, 2024

March 31,

2025

JuneJO, 2025

March 31,

2025

JuneJO, 2024

March 31,

2025

(Unaudited)

Audited

(Unaudited)

(Audited)

Unaudited

Audited

(Unaudited)

(Audited)

(Refer note 7)

(Refer note 7)

I Income:

a) Revenue from operations

11,225

6,790

5,688

30,985

16,670

13,253

11,572

55,909

b) Other income

609

380

1,662

567

859

380

2,066

Total Income

11,720

7,399

6,068

32,647

17,237

14,112

11,952

57,975

II Expenditure:

  1. Cost of raw and packing materials consumed

  2. Purchase of traded goods

6,094

114

175

1,444

-

12,401

175

7,271

201

8,332

4,024

-

21,407

760

c) Changes in inventories of finished goods, traded goods and work-in-progress

6

(3,410)

522

(2,306)

250

(3,869)

148

(2,213)

d) Employee benefits expense

2,537

2,726

2,153

9,702

4,572

4,913

3,750

17,305

e) Finance cost

600

464

321

1,546

86

104

87

388

t) Depreciation and amortisation expense

491

508

2,029

842

873

3,481

g) Other expenses

2,776

3,219

2,618

11,706

4,494

5,820

5,049

21,241

Total expenses

12,604

9,602

7,566

35,253

17,713

16,887

13,931

62,369

Ill Profit/(loss) before tax and exceptional item (1-11)

IV Exceptional items (refer note 5)

(884)

-

(2,203)

-

(1,-498)

(2,606)

-

(476)

1,132

(2,775)

2,771

(1,979)

274

(4,394)

3,599

V Profit/(loss) before tax (lll+IV)

(884)

(2,203)

(1,498)

(2,606)

656

(4)

(1,705)

VI Tax expense:

  1. Current tax (net)

-

-

-

-

-

I

-

I

b) Deferred tax charge/(created) (refer note 6)

(214)

(964)

(120)

(1,083)

260

194

(117)

Total tax expenses

(214)

(964)

(120)

(1,083)

260

195

(117)

77

  1. NetProfit/(loss) after tax for the period/year(V-VJ)

  2. Profit/(loss) for the period/year attributable to:

    1. Owners ofthe Company

    2. Non-controlling interest

      (670)

      (670)

      -

      (1,239)

      (1,239)

      -

      (1,378)

      (1,378)

      -

      (1,523)

      (1,5-23)

      396

      405

      (9)

      (199)

      (189)

      (10)

      (1,588)

      (1,580)

      (8)

      (872)

      (35)

      (837)

  3. Other comprehensive income/(loss):

    1. i) Items that will not be reclassified to profit or loss

      1. Income tax related to above

    2. i) Items that will be reclassified to profit or loss

      1. Income tax related to above

  4. Total comprehensive income/(loss) for the period/year (VII+IX)
  5. Total comprehensive income/(loss) attributable to:

    1. Owners of the Company

    2. Non-controlling interest

      - 2

      -

      -

      (668)

      (6-68)

      13

      -(3)

      -

      (1,229)

      (1,229)

      -

      -

      -

      -

      -

      (1,378)

      (1,378)

      -

      7

      (2)

      -

      -

      (1,518)

      (1,518)

      -

      (3) I

      -

      394

      -

      403

      (9)

      26

      (7)

      1-17

      (63)

      (53)

      (10)

      ( I 0) 3

      10

      -

      (1,585)

      (1,577)

      (8)

      (8)

      2

      117

      -

      (761)

      (35)

      (726)

      .....

  6. Paid-up equity share capital (face value of�I/- each)

  7. Other equity

  8. Earning/(loss) per equity share(annualised, except for quarters)

613

-

6-13

613

-

613

30,784

613

-

613

-

613

-

613

82,866

Basic and Diluted (in �)

(109)

(2.02)

(2.25) (2.49)

0.66

(0.31)

(2.59)

(1.37)



Statement ofStandalone andConsolidated Financial Results(Unaudited) for the Quarter EndedJuneJO, 2025UnauditedSe2ment-wise Revenue, Results and Capital Employed

(fin Lakh)

Particulars

JuneJO, 2025

(Unaudited)

Consolidated

Quarter Ended Consolidated MarchJI, JuneJO, March 31,

2025 2024 2025

Audited (Unaudited) (Audited) (Refer note 7)

5,445

a) Segment revenue

(i) Vaccines

11,225

6,790

5,687

30,984

(ii) Formulations

6,463

5,885

24,925

Sub total

Less: Inter segment revenue

16,-670

13,253

-

11,-572

55,909

-

Total se2mentrevenue

16,670

13,253

11,572

55,909

b) Segment results Profit(+)/ loss(-) before tax

(i) Vaccines

(425)

(1,885)

(1,327)

(1,652)

(ii) Formulations

1,081

1,881

(378)

857

Sub total

Other unallocated expenditure net of unallocated income and exceptional items

-656

-(4)

(1,-705)

(795)

-

Total Profit/(loss) before tax

656

(795)

(4) (1,705)

  1. Capital employed

Segmentassets

(i) Vaccines

87,506

89,119 76,301 89,119

(ii) Fonnulations

40,151

39,856

46,857 39,856

SubTotal

127,657

128,975

123,158 128,975

Segment liabilities

(i) Vaccines

31,321

35,087

30,484

35,087

(ii) Formulations

12,672

10,826

10,241

10,826

Sub Total

43,993

45,913

40,72S

45,913

Capital employed(Segment assets - segment liabilities)

(i) Vaccines

56,185

54,032

45,817

54,032

(ii) Formulations

27,479

29,030

36,616

29,030

Total capital employed

83,664

83,062

82,433

83,062



Earlier from Panacea Biotec

All Panacea Biotec news releases